News
-
-
COMMUNIQUÉ DE PRESSE
COMPLETION OF THE TRANSACTIONS ANNOUNCED IN DECEMBER 2024 RELATING TO THE AMENDMENT OF THE CONVERTIBLE BONDS SUBSCRIBED BY AN ENTITY AFFILIATED TO HEIGHTS CAPITAL MANAGEMENT, INC. (“HEIGHTS”) AND THE ISSUE OF A SECOND ASSIMILABLE TRANCHE
Crossject completes transactions announced in December 2024 related to amendment of convertible bonds subscribed by an entity affiliated to Heights Capital Management, Inc. Second assimilable tranche issued -
COMMUNIQUÉ DE PRESSE
German hotel operator Atomis expands abroad and takes over the renowned Hotel Kaffeemühle in the centre of Austrian capital Vienna - Atomis sets sight on further locations in the neighbouring country
German hotel operator Atomis expands abroad by acquiring Hotel Kaffeemühle in Vienna. The 76-room property marks Atomis' first venture outside Germany, with plans for further growth in Austria -
COMMUNIQUÉ DE PRESSE
Rational AG grows successfully – preliminary figures for the 2024 fiscal year
Rational AG reports successful growth with preliminary figures for the 2024 fiscal year, including sales revenue of 1.194 billion euros, EBIT margin of 26.3 percent, and strong performance in America and Europe -
COMMUNIQUÉ DE PRESSE
LPSO Holding Ltd. publishes provisional notice of interim result of the public tender offer for all publicly held registered shares of Orascom Development Holding AG
LPSO Holding Ltd. publishes provisional notice of interim result of public tender offer for all publicly held registered shares of Orascom Development Holding AG. Offer includes 87.58% of issued share capital -
-
-
COMMUNIQUÉ DE PRESSE
Aurubis achieves robust operating result in Q1 2024/25Aurubis achieves robust operating result in Q1 2024/25
Aurubis AG reports robust Q1 2024/25 operating result with operating EBT up by 17%. Strategic growth milestones achieved. Outlook confirms strong demand for copper products -
-
COMMUNIQUÉ DE PRESSE
BIOVERSYS SUCCESSFULLY COMPLETES ITS IPO AT CHF 36 PER SHARE AND STARTS TRADING ON THE SIX SWISS EXCHANGE TOMORROW, FEBRUARY 07, 2025
BioVersys successfully completes its IPO at CHF 36 per share, listing on SIX Swiss Exchange on February 07, 2025. The biopharmaceutical company focuses on antibacterial products against multidrug-resistant bacteria
